|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/36 | |
| A61K 38/48 | |||
| A61K 9/19 | |||
| C07K 14/00 | |||
| C12N 9/64 | |||
| A61K 47/18 | |||
| A61K 9/00 | |||
| A61K 47/26 |
| (11) | Patento numeris | 3182993 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15834421.8 |
| Europos patento paraiškos padavimo data | 2015-08-20 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-06-28 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-07-01 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/046173 |
| Data | 2015-08-20 |
| (87) | Numeris | WO 2016/029061 |
| Data | 2016-02-25 |
| (30) | Numeris | Data | Šalis |
| 201462039809 P | 2014-08-20 | US |
| (72) |
WANG, Juan, US
SACHA, Gregory A., US
NGUYEN, Phuong M., US
|
| (73) |
Portola Pharmaceuticals, Inc.,
270 East Grand Avenue Suite 22, South San Francisco, California 94080,
US
|
| (54) | LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE |
| LYOPHILIZED FORMULATIONS FOR FACTOR XA ANTIDOTE |